| Trial ID: | L4751 |
| Source ID: | NCT04620590
|
| Associated Drug: |
Dapagliflozin 10 Mg [Farxiga]
|
| Title: |
An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Impaired Renal Function
|
| Interventions: |
DRUG: Dapagliflozin 10 MG [Farxiga]
|
| Outcome Measures: |
Primary: Change in 24-hr sodium excretion, To investigate change in 24-hr sodium excretion during dapagliflozin treatment between Baseline (average of Days -3 to -1) and average of Days 2 to 4 within each study group in patients with type 2 diabetes mellitus (T2DM) with impaired renal function., 24 hours |
|
| Sponsor/Collaborators: |
Sponsor: George Clinical Pty Ltd | Collaborators: University Medical Center Groningen|Ground Zero Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
17
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2021-04-20
|
| Completion Date: |
2022-04-15
|
| Results First Posted: |
|
| Last Update Posted: |
2021-09-08
|
| Locations: |
David Cherney, CM, PhD, Toronto, Ontario, M5G 2C4, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT04620590
|
